Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/103852/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Mellington, F. E., Dayan, Colin M. ORCID: <https://orcid.org/0000-0002-6557-3462>, Dickinson, A. J., Hickey, J. L., MacEwen, C. J., McLaren, J., Perros, P., Rose, G. E., Uddin, J., Vaidya, B., Foley, P., Lazarus, J. H., Mitchell, A. and Ezra, D. G. 2017. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. *Orbit* 36 (3) , pp. 159-169. 10.1080/01676830.2017.1280057 file

Publishers page: <http://dx.doi.org/10.1080/01676830.2017.1280057>
<<http://dx.doi.org/10.1080/01676830.2017.1280057>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.

1 **Introduction**

2 Thyroid eye disease (TED) is an autoimmune inflammatory disease affecting
3 the orbit and periorbital tissues. Previous studies have reported age-adjusted
4 annual incidence rates of 42/million for TED of all severity (10/million for
5 moderate to severe disease),¹ and a prevalence of 0.25% within the
6 developed world.^{2,3} Although the natural history of TED remains unclear, it
7 typically has a period of activity over 6 to 12 months followed by slow
8 improvement over 2 to 3 years.⁴ The disease may be disfiguring and has
9 been shown to have a significant impact on physical and psychosocial
10 wellbeing.^{2,5-7} As cheap and safe interventions may prevent progression from
11 mild to severe TED⁸, there is an unmet need for early diagnosis, referral and
12 treatment of these patients and these are key factors influencing patient
13 outcome. For example, immunosuppressive therapies are most effective in
14 the early active stages of TED and missing this window of opportunity is
15 associated with worse outcomes.^{8,9}

16 In 2009, a consensus group of world opinion leaders on TED proposed the
17 “Amsterdam Declaration”, that pledged to improve the care of patients with
18 this condition.¹⁰ The Amsterdam Declaration set out a number of 5-year
19 targets aimed at referral timelines and treatment strategies. They included: to
20 halve the time from presentation to diagnosis of TED, and from diagnosis of
21 TED to referral to a centre of excellence; appropriate management of thyroid
22 dysfunction including use of radioiodine; and, the implementation of vigorous
23 anti-smoking measures in patients with or at risk of developing TED.¹⁰

The Thyroid Eye Disease Amsterdam Declaration Implementation Group UK (TEAMeD) was formed in 2010 in order to promote the objectives of the Amsterdam Declaration in the United Kingdom (UK). It comprises twelve representatives from key professional and patient-led stakeholders (including The Royal College of Ophthalmologists, the British Thyroid Association, the British Thyroid Foundation and the Thyroid Eye Disease Charitable Trust).^{10,11} UK centres for the management of TED in the United Kingdom were invited to participate in an audit to provide baseline data in order to better define the Amsterdam 5-year targets and to highlight any major deficiencies in the current level of care provided for patients with TED in the United Kingdom.

Materials and methods

The National thyroid eye disease audit (UK) was a prospective non-randomised cross-sectional multicentre observational study. The seven hospital departments who responded to the survey were: Moorfields Eye Hospital, London; University Hospital Cardiff; Royal Devon and Exeter Hospital; Queen's Medical Centre, Nottingham; Queen Victoria Hospital, East Grinstead; Royal Hallamshire Hospital, Sheffield and Southampton General Hospital.

During a three-month period from 01 June to 31 August 2014, consecutive adult patients with TED who presented to the specialist eye clinics at participating tertiary eye centres for the first time were asked (along with their examining ophthalmologist), to complete a standardised questionnaire.

48 The questionnaire focused on the key 5-year targets of the Amsterdam
49 Declaration and had six main domains: demographic information (age,
50 gender); time from diagnosis to referral to a specialist centre; time from first
51 symptoms to diagnosis; time from referral to review in tertiary centre;
52 management of thyroid dysfunction; smoking; and thyroid eye disease
53 classification (Appendix 1). Patients were identified as having “active” or
54 “inactive” TED, based on the examiners’ overall clinical impression and the
55 clinical activity score (CAS) (with a CAS of ≥ 3 being considered “active”).¹²
56 The examining clinician interpreted the CAS in the context of the examination
57 findings – for example, whether lid swelling was attributed to fat prolapse
58 rather than eyelid oedema and after consideration of any clear history of a
59 recent change in symptoms. This definition of active disease was the same as
60 that employed by Perros *et al.*¹⁵

61

62 All patients underwent a comprehensive ophthalmological examination
63 including best-corrected visual acuity obtained with a Snellen chart, slit lamp
64 biomicroscopy, exophthalmometry, Ishihara colour testing and assessment of
65 ocular motility. Eye signs were assessed according to established European
66 Group on Graves’ Orbitopathy (EUGOGO) protocols.^{13,14}

67

68 STATISTICAL ANALYSIS

69 Completed forms were collated and analysed using summary statistics only.
70 The study protocol was approved by Moorfields Eye Hospital, the lead centre
71 for the study. The study was performed in compliance with good clinical
72 practice guidelines and in accordance with the principles of the Declaration of

Helsinki. Verbal consent was obtained from each patient after explanation of the purpose and process of the study.

Results

PATIENTS AND DEMOGRAPHICS

Ninety-one patients (77 females; 85%) entered the study at a mean age 47.8 years (SD14.1; median 48; range 19-80 years); the female:male ratio was 6:1. Fifteen questionnaires were returned without sufficient information to determine their specialist centre of origin and they were included in a group labelled 'Other' (Table 1).

DURATION OF SYMPTOMS

The median time was 2 months (range 0-204) between the first visit to any doctor with symptoms, until establishing a diagnosis of TED; the patient who waited 204 months for a diagnosis had inactive TED. The median time from diagnosis to initiating referral to a specialist eye clinic was 1.13 (range 0-72) months; it then took another median delay of 1 month (range 0-29) from the referral letter to actual review in a specialist eye clinic. Overall, the median time from first symptoms of thyroid eye disease to review in a specialist eye clinic was 7 months (range 0-600) (Figure 1).

MANAGEMENT OF THYROID DYSFUNCTION

The patient-reported management of thyroid dysfunction, including relapse of hyperthyroidism, was based on patients' testimony: that is, information the patients might have received from their doctor(s) prior to the specialist clinic appointment and/or their perception of recurrent symptoms of abnormal

thyroid function. (Appendix 1). At the first specialist clinic appointment, 11% (10/91) patients reported still being hyperthyroid, 27% (25/91) reported a recurrence or 'relapse' of hyperthyroidism, and 22% (20/91) reported being hypothyroid in the last 2 years. Patients took a median of 6 months to control their thyroid function (range 0-60 months), 54% patients did not know their current thyroid status, and at least one quarter of patients reported episodes of dysthyroidism since their diagnosis (27% hyperthyroid).

RADIOIODINE

Thirteen percent (12/91) patients received radio-iodine, 3 of whom had thyroid eye disease at the time; 2 of these 3 patients had active TED and received prophylactic systemic steroids.

Seven patients (all female) received radio-iodine whilst not having TED, but developed TED at a later date; their mean age at time of radio-iodine was 49 years, and all had a history of poor thyroid control (2 were still hyperthyroid, 3 didn't know their thyroid status, one had never been euthyroid and another took 10 months to become euthyroid). Four of the 7 had relapse of hyperthyroidism and 4/7 had been hypothyroid in last 2 years. Five out of 7 (71%) were smokers, of whom 4/5 (80%) had moderate to severe TED, whereas the 2 non-smokers had mild TED. The mean Clinical Activity Score (CAS) for these 7 patients was 2.5 (SD1.98, median 2, range 0-6), with 5/7 having "active" disease.

SMOKING AND PATIENT AWARENESS OF THE IMPACT OF SMOKING ON TED

Twenty-seven patients (30%) were current smokers and 28/91 (31%) were ex-smokers, but only 63% of the current smokers had been offered smoking cessation advice -- which was usually provided by the GP or the specialist eye clinic. Counselling and written information were the most common forms of help provided to encourage smoking cessation (Figure 2), with no clear difference in the modes of help provided across the different eye centres. Only one-third of patients (31%) were aware that smoking has an adverse effect on TED, although a quarter (26%) knew that treatments for TED (e.g. steroids/radiotherapy/surgery) are more effective in non-smokers or ex-smokers than current smokers. A fifth of patients (22%) knew a successful cure of thyrotoxicosis with anti-thyroid drugs was more likely in non-smokers, than in smokers (Table 2).

THYROID EYE DISEASE CLASSIFICATION

The mean CAS at presentation was 2/7 (SD 2.04; median 2; range 0-7) and 65% had “active” disease: 46% patients had sufficient swelling to warrant treatment. 54% had no diplopia, 23% had intermittent diplopia, 8% had inconstant diplopia and 29% had constant diplopia. Seven percent were deemed to have a ‘cornea at risk and 4% had optic neuropathy. In terms of disease severity, 43% patients had mild, 53% had moderate-to-severe, and 4% had sight-threatening disease (1 patient each at Moorfields, Nottingham and Sheffield) (Figure 3).

Discussion

Our patient population had a similar average age (48 years; SD 14 years) as that of a comparable study.¹⁵ Our gender ratio (female:male - 6:1), whilst the same as that in a recent study,¹⁶ was higher than the 3:1 reported by Perros *et al* in 2012.¹⁵

The importance of early diagnosis and management to prevent progression of TED has been well documented. For patients with mild TED, a 6-month course of oral selenium (100 µg twice daily) was shown to significantly improve quality of life, reduce ocular involvement, and slow progression of the disease.¹⁷ Immunosuppressants such as systemic corticosteroids or orbital radiation) are only effective during the “active” phase of TED and so it is imperative that patients are identified and treated early, and the opportunity for effective intervention is not missed.¹⁸

In 2008, Sasim *et al*¹⁹ found that 75% of patients with TED seen at a specialist eye centre had had the disease for over a year. Estcourt *et al*⁹ reported that 33% of respondents waited more than 6 months from first consultation with any doctor to review at a specialist clinic; they also showed that patients treated at a specialist TED clinic were more likely to be satisfied with their ophthalmic treatment than those who did not attend a specialist clinic, and also that most UK patients with TED never reach specialist TED clinics or were referred too late. Their study also showed delays in diagnosis and referral of TED, limited access to specialist TED clinics and low patient satisfaction with treatment.⁹

Our study has shown a median of 2 months (range 0-204) between patients seeing their first physician for ophthalmic symptoms and the diagnosis of TED, this being a favourable result compared to the PREGO study¹⁵ in which the median wait was 9 months (range 0-552) in 2012 and 16 months in 2000. Likewise, Estcourt *et al*⁹ showed 26% of survey responders waited more than 12 months from first symptoms to diagnosis in the UK.

The median time from first TED symptoms to review in a specialist eye clinic was 7 (range 0-600) months (Figure 1), this comparing well with a European multi-centre study that reported a median of 9 months in 2012 from first TED symptoms to diagnosis, and then a further median of 6 months from diagnosis to first specialist clinic appointment.¹⁵ Our study took place two years after the PREGO study¹⁵ and our shorter timelines may be attributed to a general improvement in TED awareness and access to specialist treatment; alternatively, our results might suggest that the UK National Health Service (NHS) is performing better than European Healthcare systems in this regard.

Patients with uncontrolled thyroid function are more likely to develop TED and have more severe disease^{20,21} and 54% of our patients did not know their current thyroid status: over half (54%) of patients were unsure of how long it took for their thyroid levels to become normal after diagnosis of thyroid eye disease, 18% were unaware of any relapses of hyperthyroidism, and 14% patients did not know if they had become hypothyroid in past 2 years. As current guidance recommends prompt achievement and maintenance of a euthyroid state in patients with newly diagnosed TED,^{4,12} patients should be

encouraged to monitor their thyroid status and be informed of the association between uncontrolled thyroid levels and likelihood of more severe disease. This is in keeping with UK Government policy in which the NHS Outcomes Framework 2015/6 pledges improved support for people in managing their chronic disease.²² Emphasis should be placed on achieving and maintaining normal thyroid levels, and such knowledge might promote improved compliance with medications and management of thyroid dysfunction. All doctors (General practitioners, Endocrinologists and Ophthalmologists) involved in care of patients with TED should keep them informed of their thyroid status and improved access of patients to their health records and test results may facilitate this; NHS England has declared that, by April 2016, online patient records should include test results accessible to the patient.²³

RADIOIODINE AND STEROID PROPHYLAXIS

All patients in our study who received radioiodine for active TED were given prophylactic steroids,¹⁰ but 7/12 (58%) patients having radioiodine developed TED only after the treatment. In line with earlier studies,²⁴ 5 of these 7 (71%) were smokers with poor thyroid control – that is, 4/7 had relapse of hyperthyroidism, and 4/7 had been hypothyroid in the preceding 2 years). These findings confirm the deleterious association of both smoking and thyroid dysfunction with TED: two key factors that have been consistently associated with worse outcomes.²⁴⁻²⁸

SMOKING AND PATIENT AWARENESS OF ITS IMPACT ON AUTOIMMUNE THYROTOXICOSIS AND TED

It is repeatedly reported that the proportion of smokers in cohorts with TED is higher than the general population,¹⁵ and in our study, this was 30% current smokers, compared to 19% of the UK population.²⁹ The numbers were even higher in Europe with 40% current smokers reported by Perros *et al*¹⁵ in their European-based prospective observational study of 269 new referrals with Graves' orbitopathy compared to 28% of the overall adult population. Europe has the highest prevalence of tobacco smoking in the world (28% vs. 21% world adult population).³⁰

The association between smoking and TED is well-established: smoking has a dose-dependent association with severity of TED,²⁶ is associated with exacerbation of TED after radio-iodine therapy, and is an independent risk factor for a poor response to immunosuppression.²⁸ The exact mechanisms underlying this relationship are not yet clearly defined, although oxidants and free radicals contained in tobacco smoke are thought to increase oxidative stress.³¹ Hyaluronic acid production and adipogenesis are stimulated by cigarette smoke in a dose-dependent manner.³²

Our study suggests that not enough patients are being provided with advice about smoking cessation, or information about the impact of smoking on TED and control of thyroid function. Most patients were unaware that smoking increases the risk of worse TED, reduces the effectiveness of treatments for TED, and reduces the chance of being cured of hyperthyroidism. (Table 2). More than one-third (37%) of our current smokers had not been offered smoking cessation advice, and yet a quarter of patients who had been

smokers at the time of first thyroid diagnosis subsequently stopped; this latter figure is a higher than expected, as a meta-analysis of smoking cessation rates reporting only a 7% rate after intervention with nurse-led patient education.³³ This might suggest that educating patients about the impact of smoking on their disease can be effective in TED.³⁴

Since smoking is such an important modifiable risk factor, it is imperative that all current smokers with thyroid gland disease are provided with smoking cessation support.^{4,10} The 5-year target is: all patients seen in the specialist eye clinic should be provided with verbal information on the impact of smoking on TED and all current smokers should receive written information on smoking cessation. Patient-led organisations such as the British Thyroid Foundation³⁵ and the Thyroid Eye Disease Charitable Trust³⁶ play a major role in supporting patients with their disease and are an important source of disease-specific information. In accordance with NICE guidance, all current smokers in the UK should be offered a range of cessation strategies – for example, smoking cessation medications, cognitive behaviour therapy, acupuncture - by their General Practitioner as part of NHS Stop Smoking Services.³⁷

TED CLASSIFICATION

At first ophthalmic assessment, our patients had more active and more severe disease than that reported by Perros *et al* in 2012 (active disease 65% vs. 36.8%; mild disease 43% vs. 60.5% respectively)¹⁵ (Figure 3). This may be attributed to earlier diagnosis of TED in our study (median 2 vs. 9 months)

and this difference may be independent of smoking habits since more severe disease might be expected in Europe, where more patients smoke.^{15,30}

LIMITATIONS AND FINDINGS OF THE STUDY

The study is limited by a lack of independent validation of patient responses to the questionnaire. Information about management of thyroid dysfunction was collected solely from the patient's testimony. The questionnaire did not include questions on past medical history including diabetic status, or current medication including anti-thyroid medication and selenium supplementation.

As such, the history of thyroid status, treatment and current thyroid status were unverified from medical records. This limits conclusions that can be drawn about thyroid status at the time of specialist ophthalmic assessment and the incidence of relapse of thyrotoxicosis. Furthermore, since monotherapy with anti-thyroid drugs such as thiamazol may lead to poorly controlled thyroid levels, and given that the dose-response relationship of selenium levels may be non-linear in diabetics³⁸, in addition to concerns that high selenium levels may increase the risk of high grade prostate cancer³⁹, future studies in this area may benefit from collecting data on the type of thyroid medication used, selenium supplementation and diabetic status.

The study did not include the paediatric population and therefore cannot draw any conclusions as to the current level of care for children with thyroid eye disease in the United Kingdom. The authors would welcome future research in this patient demographic.

As a result of this study, we have gained a new insight into the current level of care of patients with TED in the United Kingdom, and this data provides a baseline against which the Amsterdam Declaration targets can be assessed in the future. The study has generally shown a consistent pattern of patient profiles, knowledge and management across the different recruiting centres, but patients would appear to be still waiting a long time not only from first symptoms to diagnosis, but also from diagnosis to ophthalmic assessment. The findings of this study support changes to practice particularly with respect to patient education and awareness of disease and the factors which influence its progression and prognosis, namely thyroid dysfunction and smoking. This is in line with the Amsterdam Declaration recommendation of vigorous anti-smoking measures.

In this study, we found complete adherence to the Amsterdam Declaration recommendation that all patients with thyroid eye disease undergoing radioiodine therapy should have prophylactic steroids to prevent worsening of their disease. The study has enabled greater definition of national 5-year targets based on the goals of the Amsterdam Declaration and this will facilitate planned future re-audit.

Conflict of interest

None registered.

Acknowledgements

Professor Geoffrey E. Rose and Mr Daniel G. Ezra acknowledge support by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Members of the Amsterdam Declaration (Appendix 2).

References

1. Abraham-Nordling M, Bystrom K, Toring O, Lantz M, Berg G, Calissendorff J *et al.* Incidence of hyperthyroidism in Sweden. *Eur J Endocrinol* 2011;165:899-905.
2. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of Graves' orbitopathy. *J Clin Endocrinol Metab* 2013;98(1):145-52.
3. Lazarus JH. Epidemiology of Graves' Orbitopathy (GO) and relationship with thyroid disease. *Best Pract Res Clin Endocrinol Metab.* 2012 Jun;26(3):273-9.
4. Perros P, Dayan C, Dickinson J, Ezra D, Estcourt S, Foley P, *et al.* Management of patients with Graves' orbitopathy: initial assessment, management outside specialized centres and referral pathways. *Clinical Medicine* 2015;15(2):173–8.
5. Marcocci C, Altea MA, Leo M. Treatment options for Graves' orbitopathy. *Expert Opin Pharmacother* 2012;13(6):795-806.
6. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves' orbitopathy. *Clin Endocrinol* 2005;63(4):395-402.

- 346 7. Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA.
347 Assessing quality of life in Australian patients with Graves'
348 ophthalmopathy. *Br J Ophthalmol*. 2004; 88(1):75-8.
- 349 8. Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity
350 score as a guide in the management of patients with Graves'
351 ophthalmopathy. *Clinical Endocrinology* 1997;47:9-14.
- 352 9. Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B. The patient
353 experience of services for thyroid eye disease in the United Kingdom:
354 results of a nationwide survey. *Eur J Endocrinol* 2009;161(3):483-7.
- 355 10. Perros P, Wiersinga WM. The Amsterdam Declaration on Graves'
356 orbitopathy. *Thyroid* 2010;20(3):245-6.
- 357 11. Thyroid Eye disease Amsterdam Declaration Implementation Group UK.
358 TEAMeD. Available online at [www.btf-](http://www.btf-thyroid.org/index.php/campaigns/teamed)
359 [thyroid.org/index.php/campaigns/teamed](http://www.btf-thyroid.org/index.php/campaigns/teamed) [Accessed 21 December 2015].
- 360 12. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P,
361 Marcocci C *et al*. Consensus statement of the European Group on Graves'
362 orbitopathy (EUGOGO) on management of GO. *Eur J Endocrinol*
363 2008;158:273–85.
- 364 13. <http://www.eugogo.eu>
- 365 14. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis
366 K *et al*. Clinical assessment of patients with Graves' orbitopathy: the
367 European Group on Graves' Orbitopathy recommendations to generalists,
368 specialists and clinical researchers. *Eur J Endocrinol* 2006;155:387-9.
- 369 15. Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, *et al*.
370 PREGO (presentation of Graves' orbitopathy) study: changes in referral

- patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. *Br J Ophthalmol* 2015;99:1531-1535.
16. Thornton IL, Clark J, Sokol JA, Hite M, Nunery WR. Radiographic evidence of prominent retro and suborbicularis oculi fat in thyroid-associated orbitopathy. *Orbit*. 2015; 23:1-4.
17. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M *et al*. European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. *N Eng J Med* 2011;364(20):1920-1931.
18. Eichhorn K, Harrison AR, Bothun ED, McLoon LK, Lee MS. Ocular treatment of thyroid eye disease. *Expert Rev Ophthalmol* 2010; 5(3): 313–325.
19. Sasim IV, Berendschot TT, van Isterdael C & Mourits MP. Planning health care for patients with Graves' orbitopathy. *Graefes Arch Clin Exp Ophthalmol* 2008 246 1315–1321.
20. R. S. Bahn, H. B. Burch, D. S. Cooper, *et al*. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Endocr Pract* 2011; 17(3): 456–520.
21. Prummel MF, Wiersinga WM, Mourits MP, *et al*. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. *Arch Intern Med* 1990;150:1098–1101.
22. NHS Outcomes Framework 2015 to 2016.
<https://www.gov.uk/government/publications/nhs-outcomes-framework-2015-to-2016> [Accessed 03 January 2016].

- 395 23. NHS England Patient online.
396 <https://www.england.nhs.uk/ourwork/pe/patient-online>. [Accessed 03
397 January 2016]
- 398 24. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E *et*
399 *al.* Relation between therapy for hyperthyroidism and the course of
400 Graves' ophthalmopathy. *N Eng J Med* 1998;338:73-8.
- 401 25. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F *et*
402 *al.* More on smoking habits and Graves ophthalmopathy. *J Endocrinol*
403 *Invest* 1989; 12:733–737.
- 404 26. Prummel MF, Wiersinga WM. Smoking and risk of Graves disease. *JAMA*
405 1993; 269:479–482.
- 406 27. Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann
407 K *et al.* Impact of smoking on the response to treatment of thyroid
408 associated ophthalmopathy. *Br J Ophthalmol* 2003; 87:773–776.
- 409 28. Xing, L. Ye L, Zhu W, Shen L, Huang F, Jiao Q *et al.* Smoking was
410 associated with poor response to intravenous steroids therapy in Graves'
411 ophthalmopathy. *Br J Ophthalmol* 2015;99(12):1686-91.
- 412 29. Statistics on smoking. England 2015. Published online 29 May 2015.
413 <https://www.hscic.gov.uk> [Accessed 03 January 2016].
- 414 30. Prevalence of tobacco use. World Health Organisation Global Health
415 Observatory (GHO) data. <https://www.who.it/gho/tobacco/use/en/>
416 [Accessed 03 January 2016].
- 417 31. Tsai CC, Cheng CY, Liu CY, Kao SC, Kau HC, Hsu WM *et al.* Oxidative
418 stress in patients with Graves' ophthalmopathy: relationship between
419 oxidative DNA damage and clinical evolution. *Eye* 2009;23:1725–30.

32. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. *J Clin Endocrinol Metab* 2007;92:59–64.
33. Rice VH, Stead LF. Nursing interventions for smoking cessation. *Cochrane Database Syst Rev* 2004;(1):CD001188
34. Hartmann-Boyce J, Lancaster T, Stead LF. Print-based self-help interventions for smoking cessation. *Cochrane Database Syst Rev* 2014 Jun 3;6:CD001118.
35. The British Thyroid Foundation. <https://www.btf-thyroid.org> [Accessed 03 January 2016].
36. The Thyroid Eye Disease Charitable Trust (TEDct. <https://www.TECct.org.uk> [Accessed 03 January 2016].
37. Stop smoking services. Guidance and guidelines. NICE guidelines [PH10]. Published February 2008. <https://www.nice.org.uk/guidance/ph10> [Accessed 03 January 2016].
38. Wang XL, Yang TB, Wei J, Lei GH, Zeng C. Association between serum selenium level and type 2 diabetes mellitus: a non-linear dose-response meta-analysis of observational studies. *Nutr J* 2016; 15(1): 48.
39. Gontero P, Marra G, Soria FA, Oderda M, Zitella A, Baratta F *et al.* A randomised double-blinded placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”? *Prostate* 2015; 75(11):1177-86.

Titles and legends to figures

444 Table 1. To show the baseline characteristics and the distribution of the
445 patients across the different specialist eye centres involved in the study.
446 Key: MEH = Moorfields Eye Hospital, London; Notts = Nottingham University
447 Hospitals NHS Trust; QVH = Queen Victoria Hospital, East Grinstead; Other =
448 questionnaires of indeterminate origin (that is, returned without sufficient
449 information to determine which tertiary centre they were from).

450

451 Figure 1. To show the median time (months) from first symptoms of thyroid
452 eye disease to specialist eye clinic appointment. Key: MEH = Moorfields Eye
453 Hospital, London; Notts = Nottingham University Hospitals NHS Trust; QVH =
454 Queen Victoria Hospital, East Grinstead; Other = questionnaires of
455 indeterminate origin (that is, returned without sufficient information to
456 determine which tertiary centre they were from).

457 Figure 2. To show the frequency and range of smoking cessation support
458 offered to patients. Key: CBT = Cognitive behavioural therapy; Written info =
459 written information.

460 Figure 3. To show the distribution of TED disease activity and severity. Key
461 CAS = Clinical activity score.

462

463 Table 2. To show the variation of patient awareness of the impact of smoking
464 on thyroid eye disease, the efficacy of treatment of thyroid eye disease and
465 Graves' disease across the different specialist eye clinics. Key: MEH =
466 Moorfields Eye Hospital, London; Notts = Nottingham University Hospitals
467 NHS Trust; QVH = Queen Victoria Hospital, East Grinstead; Other =

468 questionnaires of indeterminate origin (that is, returned without sufficient
469 information to determine which tertiary centre they were from).

470

471 Appendix 1

472 Questionnaire: data collection proforma.

473

474 Appendix 2

475 Signatories of the Amsterdam Declaration

476 International Professional Organisations

477 Academia Ophthalmologica Europea

478 Academia Ophthalmologica Internationalis

479 American Thyroid Association

480 Asia-Oceania Thyroid Association

481 Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery

482 Endocrine Society

483 European Association for Vision and Eye Research (EVER)

484 European Group on Graves' Orbitopathy

485 European Society of Endocrinology

486 European Society of Orbital Plastic Reconstructive Surgery

487 European Thyroid Association

488 Iberico-American Society of Ophthalmic Plastic and Orbital Surgery

489 International Thyroid Eye Disease Study Group

490 Latin-American Thyroid Society

491 World Society of Pediatric Ophthalmology and Strabismus (WSPOS)

492 International thyroid patient association

- 493 Thyroid Federation International
- 494 National professional organisations
- 495 All India Ophthalmological Society
- 496 American Association of Clinical Endocrinologists
- 497 Argentina Council of Ophthalmology (Consejo Argentino de Oftalmologia)
- 498 Argentina Society of Ophthalmology (SAO)
- 499 Belgian Endocrine Society
- 500 Belgian Thyroid Club
- 501 Bielschowsky-Gesellschaft für Schielforschung und Neuroophthalmologie
- 502 British Oculoplastic Surgery Society
- 503 British Thyroid Association
- 504 Chinese Society of Ophthalmology
- 505 Cyprus Endocrine Society
- 506 Danish Thyroid Association
- 507 Dutch Endocrine Society
- 508 Finnish Endocrine Society
- 509 French Endocrine Society
- 510 French Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery
- 511 German Endocrine Society
- 512 The Amsterdam Declaration on Graves' Orbitopathy 269
- 513 German Thyroid Board
- 514 German Society of Ophthalmology (Deutsche Ophthalmologische
- 515 Gesellschaft)
- 516 Hellenic Endocrine Society
- 517 Hellenic Society of Ophthalmic Plastic and Reconstructive Surgery

- 518 Irish Endocrine Society
- 519 Italian Association of Medical Endocrinologists (Associazione Medici
- 520 Endocrinologi)
- 521 Italian Society of Endocrinology
- 522 Italian Society of Ophthalmic Plastic Surgery (Società Italiana di Chirurgia
- 523 Oftalmoplastica, SICOP)
- 524 Italian Thyroid Association
- 525 Japan Thyroid Association
- 526 Japanese Society of Ophthalmology
- 527 Macedonian Endocrine Association
- 528 Oculoplastic Association of India
- 529 Ophthalmological Society of Portorico (Sociedad Puertorriqueña de
- 530 Oftalmología)
- 531 Philippine Society of Ophthalmic Plastic and Reconstructive Surgery
- 532 (PSOPRS)
- 533 Philippine Academy of Ophthalmology (PAO)
- 534 Polish Thyroid Society
- 535 Romanian Society for Endocrinology
- 536 Royal College of Ophthalmologists (UK)
- 537 Serbian Endocrine Society
- 538 Slovak Endocrine Society
- 539 Società Oftalmologica Italiana
- 540 Society for Endocrinology (UK)
- 541 South African Society of Oculoplastic Surgeons

- 542 Spanish Society of Ophthalmic Plastic and Orbital Surgery (Sociedad
- 543 Espanola de
- 544 Cirurgia Plastica Ocular y Orbitaria, SECPOO)
- 545 Swiss Endocrine and Diabetes Society (SGED/SSSED)
- 546 Turkish Society for Endocrinology and Metabolism
- 547 National thyroid patient organisations
- 548 Association “Vivre sans Thyroïde”
- 549 British Thyroid Foundation
- 550 Finnish Thyroid Foundation
- 551 Georgian Union of Diabetes and Endocrine Associations (GUDEAS)
- 552 Italian Thyroid Patient Association
- 553 La Asociación Mexicana de Tiroides
- 554 Nederlandse Vereniging van Graves’ patienten
- 555 Norsk Thyreoideaforbund
- 556 Ohne Schilddrüse leben e.V.
- 557 Schilddrüsen-Liga Deutschland e.V.
- 558 Schilddrüsenstichting Nederland (Thyroid Patients Organization of the
- 559 Netherlands)
- 560 Svenska Sköldkörtel Föreningen.
- 561 The Australian Thyroid Foundation Ltd.
- 562 Thyroid Australia
- 563 Thyroid Eye Disease charitable trust (UK)
- 564 Thyreoidea Landsforeningen
- 565 Instituto da Tiroide
- 566 Japan Thyroid Foundation

- 567 Thyroid Foundation of Canada / La Fondation canadienne de la Thyroïde
- 568 Thyroid Foundation of St. Petersburg
- 569 United States of America Graves' Disease Foundation
- 570 Verein Schilddru sengruppe Schweiz